课题基金 / 基金详情

To Test A Payer/Treatment Agency Intervention to Increase Use of Buprenorphine

To Test A Payer/Treatment Agency Intervention to Increase Use of Buprenorphine
测试付款人/治疗机构干预以增加丁丙诺啡的使用
批准号:
8434849
负责人:
Todd David Molfenter
金额:
$61.59万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-03-01 至 2017-02-28

项目摘要

项目成果

Todd David Molfenter的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A team of researchers from the University of Wisconsin-Madison College of Engineering and Oregon Health & Science University will test whether clinician training and the use of organizational change strategies are sufficient for disseminating an evidence-based practice (EBP), or if changes to both organizational systems and payer policy result in greater EBP use. Demonstrating the role of payment policy as a driver in the adoption of evidence-based practices could provide a contribution to dissemination and implementation science. This study will employ an intervention that was developed through the Robert Wood Johnson Foundation-funded Advancing Recovery (AR) program. In AR, payer/treatment organization partnerships in 12 states collaborated to remove systemic barriers to the adoption of EBPs such as medication-assisted treatment for substance abuse disorders. The resulting "AR Framework" of payer and organizational change strategies will be tested against its ability to increase the use of the addiction medication buprenorphine as compared to organizational change strategies alone. Buprenorphine is an EBP for treating people addicted to heroin or opioid-based pain medications for non-medical use. Buprenorphine has experienced low adoption rates and is not a standard part of addiction treatment. In Ohio, the location of the study, deaths to due to accidental opioid overdoses have increased by 304% over the past decade and surpassed auto accidents as the leading cause of accidental deaths in 2006. Ohio was selected for the study because of the public health significance of opioid abuse and because each county in Ohio acts as a stand-alone payer, offering 48 unique eligible payer environments. This trial will develop a deeper understanding of the role payers and treatment organizations play in implementing and disseminating EBPs and will focus on the public health issue of rising opioid abuse.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
No-Show Prevention Practices in Dental Care Settings Serving Underserved Populations
  • 批准号:
    10367495
  • 项目类别:
  • 资助金额:
    $33.74万
  • 财政年份:
    2022
  • 负责人:
    Todd David Molfenter
  • 依托单位:
No-Show Prevention Practices in Dental Care Settings Serving Underserved Populations
  • 批准号:
    10559683
  • 项目类别:
  • 资助金额:
    $30.73万
  • 财政年份:
    2022
  • 负责人:
    Todd David Molfenter
  • 依托单位:
Test of a Workforce Development Intervention to Expand Buprenorphine Prescribers
  • 批准号:
    9080813
  • 项目类别:
  • 资助金额:
    $63.1万
  • 财政年份:
    2016
  • 负责人:
    Todd David Molfenter
  • 依托单位:
To Test A Payer/Treatment Agency Intervention to Increase Use of Buprenorphine
  • 批准号:
    8607921
  • 项目类别:
  • 资助金额:
    $63.53万
  • 财政年份:
    2012
  • 负责人:
    Todd David Molfenter
  • 依托单位:
海外基金